What the studies found
Semaglutide has been tested for weight, heart trouble, and kidney disease, and it copies 1 gut hormone
The sales claims are broad. The studies show what changed, who was tested, and which doubts remain.
What did the large studies measure?
Large studies checked weight, blood sugar, heart trouble, and kidney loss. Semaglutide helped some people on each measure. In people with diabetes and kidney disease, kidney loss slowed [6].
Semaglutide copies GLP-1, made in your gut after meals. The hormone helps you feel full and steadies blood sugar. Doctors may prescribe the drug for type 2 diabetes or long-term weight control. It can also lower certain heart risks. Since 2025, doctors may use it for MASH, a serious fatty-liver illness. The shot is weekly. The pill is daily. Nausea was the leading complaint, mainly at first. You'll find patient reports on the effects page.
The gains were real for those groups. The drug still caused trouble.
What do the main trials say?
Semaglutide is a 31-amino-acid chain, made from small protein building blocks. It belongs to the GLP-1 group. GLP-1 is short for the gut hormone the drug copies. The GLP-1 message helps steady blood sugar and ease hunger.
One heart study followed 17,604 adults. Each was overweight and had heart disease; no one had diabetes. A 2.4 mg weekly shot cut major heart problems by 20% against placebo, a look-alike treatment with no drug [3]. The 95% figure tells how sure researchers were, not how many people benefited. Their full check still favored Semaglutide. STEP 1 tested the same amount for weight loss. After 68 weeks, the drug group lost much more weight than the placebo group [1]. SUSTAIN-6 tested adults with type 2 diabetes. It also counted fewer serious heart events [2]. Its own 95% certainty check pointed the same way.
The brochure likes those results. They're group averages, not your forecast.
What did the kidney study find?
In 2024, a kidney study followed 3,533 adults. Every participant had lasting kidney disease along with type 2 diabetes. A weekly 1.0 mg shot led to 24% fewer major kidney events than placebo [6]. Its 95% figure describes how sure the researchers were, not your personal odds. The full check favored the drug. It counted kidney failure, kidney- or heart-linked death, and a 50% fall in the kidneys' cleaning work.
A later review asked if the heart gain held as kidney illness grew worse. The gain held across the groups studied [12]. Semaglutide also sticks to the blood protein albumin. That slows removal of the drug through the kidneys.
The kidney finding is strong for those patients. It doesn't cover everyone.
Why did compounded Semaglutide change?
Semaglutide has approved uses and two forms. A shot is given weekly; a pill is taken daily. Doctors may use it for type 2 diabetes, long-term weight control, some heart risks, and MASH [9]. MASH is a serious fatty-liver illness.
The shortage ran from about 2022 until early 2025. During that gap, federal rules let special pharmacies mix their own versions. The opening narrowed when the official shortage status ended in early 2025 [9]. The main studies tested the approved drug, not each mixed version. Federal law doesn't treat the two as the same product.
That's the public record. It isn't advice about your legal rights.
Where can you read more?
A study or review supports every number. Open the full list at Semaglutide references.
For the drug's work inside you, read how does semaglutide work. For the basic facts, open what is semaglutide. The Semaglutide effects page keeps patient stories apart from study findings. That matters. One person's report can't prove that the drug caused a change.
This site explains the evidence. There's no clinic here, and no medicine is offered.